Repositioning Drugs to Treat Ischemic Stroke at Delayed Time Points
Repositioning Drugs to Treat Ischemic Stroke at Delayed Time Points
批准号:
9182582
负责人:
JOHN A SCHETZ
金额:
$21.9万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-01 至 2018-06-30
关键词:
AccelerationAcuteAddressAffinityAgonistAmericanAnimal ModelAnimalsAnticoagulantsBehavioralBiological AssayBlood coagulationBrainBrain hemorrhageCause of DeathCell LineCell ProliferationCellsCerebral IschemiaClinical ResearchClinical TrialsCoagulation ProcessDiagnosisDistalDoseEffectivenessEvaluationFDA approvedFunding MechanismsFutureGenetic PolymorphismGoalsHealthHistone Deacetylase InhibitorHospitalsHourHumanIn VitroIncidenceInfarctionInterventionIschemic StrokeLeadMaximum Tolerated DoseMeasuresMedicalMedicineMiddle Cerebral Artery OcclusionModelingMolecular ChaperonesNerve DegenerationNervous System PhysiologyNeurogliaNeurologicNeuronsOutcomeParahippocampal GyrusPatientsPharmaceutical PreparationsPre-Clinical ModelProcessPropertyRattusRecovery of FunctionRehabilitation therapyReportingRiskRodent ModelSelection CriteriaSelective Serotonin Reuptake InhibitorSerumSiteStagingStrokeSystemTestingTherapeuticTimeTissuesUnited Statesangiogenesisbasecandidate selectionchronic strokecostcounterscreendentate gyrusdisabilitydrug candidateeffective therapyexperienceimprovedimproved outcomein vivomeetingsneurogenesisneuronal survivalneurotropicphase II trialpost strokepre-clinicalpreclinical studyprogramsreceptorrehabilitative carerepairedresiliencesecretion processsigma-1 receptorstroke recoverystroke therapysubventricular zonesynaptogenesistraffickingwhite matterwhite matter damage
中文摘要
项目摘要
缺血性脑中风每年以惊人的速度袭击大约75万美国人。
成本只有一种治疗方法被批准,并且要求在很短的时间内进行治疗。
在大多数情况下(约90%),帧(目前在美国3小时内)大大限制了其适用性。通过
我们将重点关注在延迟时间点(≥ 24小时)改善卒中结局的药物,
这是一种未得到满足的医疗需求,有可能影响大量中风患者的健康。大脑-
衍生的神经营养因子(BDNF)促进体外缺血神经元的恢复,促进功能性
在损伤后延迟时间点(≥24小时)给药时,卒中动物模型的恢复情况,及其
水平与中风患者的功能恢复呈正相关。由于加工和分泌的
体外激活神经胶质细胞和神经元细胞中的Sigma-1受体(S1 R)伴侣可增强BDNF
在体内的大脑中,我们试图发现现有的药物,凭借它们与大脑的相互作用,
S1 R可能在延迟时间点重新用于缺血性卒中的功能恢复。我们的目标
包括开发体外和体内测定平台,以合理地指导用于在体外和体内测定的候选物的选择,
在啮齿动物局灶性脑缺血模型中的体内评价。这项探索性应用的结果将
为未来资助机制支持的重点转化药物再利用工作奠定基础。
英文摘要
Project Summary
Ischemic cerebral stroke attacks approximately three quarters of a million Americans each year at a staggering
cost. Only one treatment has been approved and the requirement that it be administered within a narrow time
frame (currently within 3 hrs in the USA) drastically limits its applicability in the majority of cases (~90%). By
focusing on medicines for improved stroke outcomes at delayed time points (≥ 24 hours), we will be addressing
an unmet medical need that has the potential to impact the health of large numbers of stroke victims. Brain-
derived Neurotropic Factor (BDNF) promotes the resilience of ischemic neurons in vitro, promotes functional
recovery in animal models of stroke when administered at delayed time points after the insult (≥24 hrs), and its
levels positively correlate with functional recovery in stroke patients. Since the processing and secretion of
BDNF can be enhanced by activating the Sigma-1 receptor (S1R) chaperone in glial and neuronal cells in vitro
and in the brain in vivo, we seek to discover existing medications, which by virtue of their interactions with the
S1R, might be repurposed for the functional recovery from ischemic stroke at delayed time points. Our aims
include developing an in vitro and in vivo assay platform to rationally guide the selection of candidates for in
vivo evaluation in a rodent model of focal cerebral ischemia. The findings from this exploratory application will
set the stage for a focused translational drug repurposing effort supported by a future funding mechanism.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neuroleptic Spacer Length Governs Molecular Recognition
-
批准号:6855715
-
项目类别:
-
资助金额:$31.74万
-
财政年份:2003
-
负责人:JOHN A SCHETZ
-
依托单位:
Neuroleptic Spacer Length Governs Molecular Recognition
-
批准号:6576167
-
项目类别:
-
资助金额:$2.8万
-
财政年份:2003
-
负责人:JOHN A SCHETZ
-
依托单位:
Neuroleptic Spacer Length Governs Molecular Recognition
-
批准号:6704192
-
项目类别:
-
资助金额:$32.82万
-
财政年份:2003
-
负责人:JOHN A SCHETZ
-
依托单位:
Neuroleptic Spacer Length Governs Molecular Recognition
-
批准号:6803562
-
项目类别:
-
资助金额:$34.82万
-
财政年份:2003
-
负责人:JOHN A SCHETZ
-
依托单位:
Neuroleptic Spacer Length Governs Molecular Recognition
-
批准号:7829979
-
项目类别:
-
资助金额:$7.84万
-
财政年份:2003
-
负责人:JOHN A SCHETZ
-
依托单位:
Neuroleptic Spacer Length Governs Molecular Recognition
-
批准号:7013247
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2003
-
负责人:JOHN A SCHETZ
-
依托单位:
Neuroleptic Spacer Length Governs Molecular Recognition
-
批准号:7176843
-
项目类别:
-
资助金额:$31.93万
-
财政年份:2003
-
负责人:JOHN A SCHETZ
-
依托单位:
海外基金